

Date: 1 August 2022

**Re: Freedom of Information Request**  
**Ref: 238-2022**

Thank you for your email dated the 8<sup>th</sup> July 2022, requesting information in relation to breast cancer treatment.

The information you require is as follows:

**In the past 3 months, (April 2022 – June 2022) how many Breast Cancer patients (any stage) were treated with:**

- **Abemaciclib monotherapy - 35**
- **Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)**
- **Tamoxifen monotherapy - We only record if this is first intervention at CCC, therefore we do not hold this information**
- **Abemaciclib + Tamoxifen - 0**
- **Abemaciclib + Tamoxifen + Goserelin - 0**
- **Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)**
- **+ Goserelin - 0**
- **Aromatase inhibitor + Goserelin - 0**
- **Tamoxifen+ Goserelin - 0**

**How many patients have been treated for Triple-Negative Breast Cancer (any stage) in the past 3 months (April 2022 – June 2022) with the following systemic anti-cancer therapies:**

- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent - 0**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel - 32**
- **Pembrolizumab - 0**
- **Sacituzumab Govitecan - 7**
- **Parp Inhibitors (Olaparib/Talazoparib) – 0**
- **Eribulin as a single agent or in combination - 18**
- **Capecitabine as a single agent - 26**

- **Platinum (e.g. carboplatin or cisplatin) as a single agent - 3**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent - 270**
- **Taxane and/or Anthracycline in combination - 0**

#### **Any other active systemic anti-cancer therapy**

- **AC -Doxorubicin Cyclophosphamide - <5**
- **Aspirin/placebo (ADD Aspirin Trial) - 21**
- **Atezolizumab - 8**
- **Carboplatin + Etoposide - 8**
- **Carboplatin + Paclitaxel - 217**
- **Cyclophosphamide + Docetaxel - 11**
- **Denosumab - 41**
- **EC - Epirubicin Cyclophosphamide - 108**
- **GemCarbo -10**
- **Paclitaxel albumin (Abraxane) - <5**
- **Paclitaxel + Pertuzumab + Trastuzumab SC - <5**
- **Palbociclib - <5**
- **Palbociclib + Fulvestrant - <5**
- **Phesgo - 11**
- **Trastuzumab Subcutaneous - 8**
- **Trastuzumab - <5**
- **Zoladex - 14**
- **Zoledronate - 112**

**Where there were less than 5 patients have been stated as <5, to maintain confidentiality and prevent the potential identification of these individuals when combined with other data sets.**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

<https://forms.office.com/r/eLzHXi49Ea>



Kind Regards,

The Information Governance Team  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)